...
首页> 外文期刊>Parasitology Research >Evaluation of protective immune response in mice by vaccination the recombinant adenovirus for expressing Schistosoma japonicum inhibitor apoptosis protein.
【24h】

Evaluation of protective immune response in mice by vaccination the recombinant adenovirus for expressing Schistosoma japonicum inhibitor apoptosis protein.

机译:通过接种重组腺病毒以表达日本血吸虫抑制剂凋亡蛋白来评估小鼠的保护性免疫应答。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Schistosomiasis is a worldwide parasitic disease, and while it can be successfully treated with chemotherapy, this does not prevent reinfection with the parasite. Adenovirus vectors have been widely used for vaccine delivery, and a vaccination approach has the potential to prevent infection with Schistosoma. Here, we developed a recombinant adenoviral vector that expresses Schistosoma japonicum inhibitor apoptosis protein (Ad-SjIAP) and assessed its immunoprotective functions against schistosomiasis in mice. Murine immune responses following vaccination were investigated using enzyme-linked immunosorbent assays (ELISA), lymphocyte proliferation, and cytokine assays. The protective immunity in mice was evaluated by challenging with S. japonicum cercariae. Our results indicated that immunization with the Ad-SjIAP in mice induced a strong serum IgG response against IAP including IgG1, IgG2a, and IgG2b. In addition, lymphocyte proliferation experiments showed that mice treated with Ad-SjIAP significantly increased the lymphocyte response upon stimulation with recombinant Schistosoma japonicum inhibitor apoptosis protein (rSjIAP). Moreover, cytokine assays indicated that vaccination of Ad-SjIAP significantly increased the production of interferon (IFN)-γ and IL-2 as compared to the corresponding control group. Furthermore, following the challenge with S. japonicum cercariae, the vaccine conferred moderate protection, with an average rate of 37.95% for worm reduction and 31.7% for egg reduction. Taken together, our preliminarily results suggested that schistosoma IAP may be a potential vaccine against S. japonicum and that adenoviral vectors may serve as an alternative delivery vehicle for schistosome vaccine development.
机译:血吸虫病是一种世界性的寄生虫病,尽管可以通过化学疗法成功治疗,但这并不能阻止该寄生虫的再感染。腺病毒载体已被广泛用于疫苗递送,并且疫苗接种方法具有预防血吸虫感染的潜力。在这里,我们开发了表达日本血吸虫抑制剂凋亡蛋白(Ad-SjIAP)的重组腺病毒载体,并评估了其对小鼠血吸虫病的免疫保护功能。使用酶联免疫吸附测定(ELISA),淋巴细胞增殖和细胞因子测定研究了接种疫苗后的小鼠免疫应答。通过用日本链球菌攻击来评估小鼠中的保护性免疫。我们的结果表明,在小鼠中用Ad-SjIAP免疫可诱导针对IAP(包括IgG1,IgG2a和IgG2b)的强烈血清IgG反应。此外,淋巴细胞增殖实验表明,用重组日本血吸虫抑制剂凋亡蛋白(rSjIAP)刺激后,用Ad-SjIAP处理的小鼠显着增加了淋巴细胞反应。此外,细胞因子测定表明,与相应的对照组相比,Ad-SjIAP的疫苗接种显着增加了干扰素(IFN)-γ和IL-2的产生。此外,在日本尾。的攻击下,该疫苗具有中等保护作用,蠕虫减少率平均为37.95%,鸡蛋减少率平均为31.7%。两者合计,我们的初步结果表明,血吸虫IAP可能是针对日本血吸虫的潜在疫苗,而腺病毒载体可以作为血吸虫疫苗开发的替代载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号